Current research on CGRP in migraine has particularly focused on drug development, emphasizing the evaluation of these drugs’ safety profiles alongside their demonstrated efficacy, as encapsulated in the articles covered in cluster #0 (Erenumab) and cluster #4 (Ubrogepant). This evidence concerns the gene CALCA and migraine disorder.